![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Objective: To assess the effect of raloxifene 60 mg/day (RLX) on year-by-year cardiovascular (CV) events in postmenopausal women participating in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial, a double-blind, placebo-controlled osteoporosis treatment trial.
Research design and methods: Post hoc analysis, using data from participants receiving placebo (N = 2576) or RLX 60 mg/day (N = 2557) in MORE, was performed to determine the relative risk (RR, 95% CI) of CV events in each individual trial year. Analyses were performed for the overall cohort and for women in high and low risk subsets. Women were retrospectively assessed as high CV risk using established criteria and the remaining women were considered low CV risk.
Results: The incidence of CV events did not differ between the RLX and placebo groups in the overall cohort (RR 0.86, 95% CI 0.64–1.15), or the low CV risk subset (RR 1.01, 95% CI 0.70–1.46). In the high-risk subset, the incidence of CV events was less in the RLX group (RR 0.60, 95% CI 0.38–0.95). There was no significant increase in CV risk during any single year in the RLX group for either the overall cohort or the low or high CV risk subsets.
Conclusion: In this post hoc analysis, the risk of CV events was not increased in any single year of MORE in women taking RLX, either in the overall cohort or in the low and high CV risk subsets.
Notes
* Material contained in this paper was presented as a poster at the 13th Annual Meeting of the North American Menopause Society, October 2–5, 2002, Chicago, ILL.